IP Library Granted Patent US 11,714,084
Granted Patent B2
US 11,714,084 · App. 17/090,383 · Granted Aug 1, 2023

Method and associated device for rapid detection of target biomolecules with enhanced sensitivity

Inventors: Matthew Jeremiah Misner (Delanson, NY); Gregory Andrew Grossmann (Halfmoon, NY); Cathryn Ellen Olsen (Wilton, NY); John Richard Nelson (Clifton, NY); Brian Christopher Bales (Niskayuna, NY); David Roger Moore (Rexford, NY); Paul Michael Smigelski, Jr. (Glenville, NY)
Assignee: General Electric Company
G01N33/5695B01D15/363B01L3/5023G01N1/4005G01N33/54366B01L2200/0631B01L2200/10B01L2300/0825G01N2001/4011G01N2333/35G01N2405/06G01N2469/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,714,084
App. No.
17/090,383
Granted
Aug 1, 2023
Kind
B2
Abstract

A rapid detection method of a target biomolecule comprising an antigenic moiety is provided. The method includes providing a source biological sample comprising the target biomolecule; contacting the source biological sample to an ion-exchange medium; eluting the captured-target biomolecule from the ion-exchange medium as an eluate, and loading the eluate to a rapid diagnostic testing device comprising an antibody. The eluate comprises a concentrated form of the biomolecule in a solution having a salt concentration greater than 150 mM. A concentration of the target biomolecule in the eluate is in a range from about 2× to 25× compared to a concentration of the biomolecule in the source biological sample. The target biomolecule binds to the antibody under the salt concentration of greater than 150 mM. A device for rapid detection of target biomolecule is also provided.

Claims (32)

1. A method for rapid diagnostic testing of a source biological sample comprising tuberculosis-lipoarabinomannan (TB-LAM), comprising:

concentrating the TB-LAM by:

diluting the source biological sample by at least 2x to form a diluted biological sample;

contacting the diluted biological sample to an anion-exchange medium to capture the TB-LAM of the diluted biological sample;

capturing the TB-LAM of the diluted biological sample by the anion-exchange medium; and

eluting captured-TB-LAM from the anion-exchange medium as a concentrated form of TB-LAM in an eluate under a salt concentration of at least 1M, wherein a concentration of the TB-LAM in the eluate is in a range from about 2x to 25x compared to a concentration of the TB-LAM in the diluted biological sample; and

loading the eluate comprising the concentrated form of the TB-LAM to a rapid diagnostic testing device comprising a TB-LAM-specific antibody for binding the concentrated form of the TB-LAM,

wherein the eluate is loaded without any dilution, and wherein the TB-LAM binds to the TB-LAM-specific antibody under the salt concentration of at least 1M.

2. The method of claim 1 , wherein the TB-LAM-specific antibody is a reporter-linked TB-LAM-specific antibody.

3. The method of claim 2 , further comprising generating a signal on binding of the TB-LAM to the TB-LAM-specific antibody in case of exceeding a pre-determined threshold value for a concentration of the TB-LAM.

4. The method of claim 1 , wherein the captured-TB-LAM binds to the TB-LAM-specific antibody under the salt concentration in a range from about 1M to 2M.

5. The method of claim 1 , wherein the captured-TB-LAM binds to the TB-LAM-specific antibody under the salt concentration of about 1.3M.

6. The method of claim 1 further comprising diluting the source biological sample by 4x to form the diluted biological sample.

7. The method of claim 1 , wherein the rapid diagnostic testing device comprises a lateral flow assay (LFA) device, an enzyme linked immuno-sorbent assay (ELISA) device, or a combination thereof.

8. The method of claim 7 , wherein the rapid diagnostic testing device comprises a lateral flow assay (LFA) device.

9. The method of claim 1 , wherein the source biological sample comprises urine, blood, feces, sweat, saliva, mucous, milk, semen, serum, plasma, sputum, tears, tissue, or combinations thereof.

10. The method of claim 9 , wherein the source biological sample is urine.

11. A device, comprising: a dilutor unit configured to dilute a biological sample; a concentrator unit configured to receive diluted biological sample from the dilutor unit via an inlet coupling the dilutor unit to the concentrator unit, the concentrator unit comprising an anion exchange medium to concentrate an antigen from the diluted biological sample and generate a concentrated form of the antigen; and an immune-based assay unit comprising an antibody to bind the concentrated form of the antigen received from the concentrator unit, wherein the concentrator unit is operatively coupled to the immune-based assay unit via an outlet to allow loading of the concentrated form of the antigen from the concentrator unit to a sample receiving zone of the immune-based assay unit.

12. The device of claim 11 , wherein the antigen is TB-LAM.

13. The device of claim 12 , wherein the immune-based assay unit comprises rapid diagnostic testing device, enzyme linked immune sorbent assay (ELISA), or lateral flow assay.

14. A method for rapid diagnostic testing of a source biological sample comprising tuberculosis-lipoarabinomannan (TB-LAM), comprising:

concentrating the TB-LAM by:

diluting the source biological sample by at least 2x to form a diluted biological sample;

contacting the diluted biological sample to an anion-exchange medium to capture the TB-LAM of the diluted biological sample;

capturing the TB-LAM of the diluted biological sample by the anion- exchange medium; and

eluting the captured-TB-LAM from the anion-exchange medium as a concentrated form of TB-LAM in an eluate under a salt concentration greater than 150 mM, wherein a concentration of the TB-LAM in the eluate is in a range from about 2x to 25x compared to a concentration of the TB-LAM in the diluted biological sample; and

loading the eluate comprising the concentrated form of the TB-LAM to a rapid diagnostic testing device comprising a TB-LAM-specific antibody for binding the concentrated form of the TB-LAM,

wherein the eluate is loaded without any dilution, and wherein the TB-LAM binds to the TB-LAM-specific antibody under the salt concentration greater than 150 mM.

15. The method of claim 14 , wherein the TB-LAM-specific antibody is a reporter-linked TB-LAM-specific antibody.

16. The method of claim 15 , further comprising generating a signal on binding of the TB-LAM to the TB-LAM-specific antibody in case of exceeding a pre-determined threshold value for a concentration of the TB-LAM.

17. The method of claim 14 further comprising diluting the source biological sample by 4x to form the diluted biological sample.

18. The method of claim 14 , wherein the source biological sample comprises urine, blood, feces, sweat, saliva, mucous, milk, semen, serum, plasma, sputum, tears, tissue, or combinations thereof.

Assignments (5)
QUITCLAIM ASSIGNMENT Recorded Sep 18, 2025
From: EDISON INNOVATIONS LLC
To: BLUE RIDGE INNOVATIONS, LLC
Reel/Frame 072938/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2025
From: GENERAL ELECTRIC COMPANY
To: GE INTELLECTUAL PROPERTY LICENSING, LLC
Reel/Frame 070636/0815 →
CHANGE OF NAME Recorded Mar 26, 2025
From: GE INTELLECTUAL PROPERTY LICENSING, LLC
To: DOLBY INTELLECTUAL PROPERTY LICENSING, LLC
Reel/Frame 070643/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2025
From: DOLBY INTELLECTUAL PROPERTY LICENSING, LLC
To: EDISON INNOVATIONS, LLC
Reel/Frame 070293/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2020
From: MISNER, MATTHEW JEREMIAH; GROSSMANN, GREGORY ANDREW; OLSEN, CATHRYN ELLEN; NELSON, JOHN RICHARD; BALES, BRIAN CHRISTOPHER; MOORE, DAVID ROGER; SMIGELSKI, PAUL MICHAEL, JR.
To: GENERAL ELECTRIC COMPANY
Reel/Frame 054288/0278 →
Continuity (2)
Continuation 15848301 · Dec 20, 2017
Related Publication 20210055297A1 · Feb 25, 2021